Please login to the form below

Not currently logged in
Email:
Password:

Piqray

This page shows the latest Piqray news and features for those working in and with pharma, biotech and healthcare.

Novartis raises 2019 guidance as new products gather speed

Novartis raises 2019 guidance as new products gather speed

and Piqray (alpelisib) for breast cancer – that both have blockbuster sales potential.

Latest news

  • FDA clears Novartis’ new breast cancer drug Piqray FDA clears Novartis’ new breast cancer drug Piqray

    Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... The approval is for Piqray (alpelisib formerly BYL719)

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics